EQT agreed on 7 July to acquire Corza Biosurgery, the business behind the TachoSil surgical patch, from GTCR-backed Corza Medical.
Why EQT (EQT X) is buying Corza Biosurgery (TachoSil)
EQT plans to invest in commercial acceleration, new indications and geographies, innovation and acquisitions, with a focus on growth in the United States.
Deal terms and financing
Terms were not disclosed. Corza Medical retains its wound closure, ophthalmology and biomedical textiles businesses.
Regulatory approvals and timing
Closing is expected in the fourth quarter of 2026, subject to customary conditions and regulatory approvals.
Market context
GTCR and Corza bought TachoSil in a 2021 corporate carve-out and combined it with Surgical Specialties. The patch is backed by more than 540 clinical trial publications.
